Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15017224 | 1.00 | TP53 (0.50) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL23573353 | 1.00 | TP53 (0.50) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL2937346 | 0.89 | TP53 (0.58) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL21813427 | 0.85 | TP53 (0.43) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL5568554 | 0.84 | MEN1 (0.38) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL1487329 | 0.84 | MEN1 (0.38) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL1487384 | 0.84 | MEN1 (0.38) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL27905521 | 0.83 | TP53 (0.51) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL20482733 | 0.80 | TSHR (0.44) | TP53ALDH1A1EPHX2EPHX1TSHR | |
| SCHEMBL21522684 | 0.78 | TP53 (0.46) | TP53ALDH1A1EPHX2EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| CN-103167867-A | Solid dispersions containing an apoptosis-inducing agent | ABBOTT LAB | 2013-06-19 | — | — | CN | disclosed |
| CN-103153993-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | TP53 2941/4885ALDH1A1 216/4885EPHX2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.